SRR8518210
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.450
- E2F_TARGETS+0.440
- MITOTIC_SPINDLE+0.390
- HEDGEHOG_SIGNALING+0.330
- DNA_REPAIR+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- MYOGENESIS+0.210
- WNT_BETA_CATENIN_SIGNALING+0.190
- UV_RESPONSE_UP+0.150
- APICAL_JUNCTION+0.110
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.510
- INTERFERON_ALPHA_RESPONSE-0.490
- IL2_STAT5_SIGNALING-0.390
- INFLAMMATORY_RESPONSE-0.370
- KRAS_SIGNALING_UP-0.360
- TNFA_SIGNALING_VIA_NFKB-0.340
- MTORC1_SIGNALING-0.310
- IL6_JAK_STAT3_SIGNALING-0.300
- COMPLEMENT-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5KO-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.843 |
| 2 | TCGA-GD-A3OS-01A-12R-A220-07 | — | — | 0.831 |
| 3 | TCGA-D8-A1XD-01A-11R-A14D-07 | — | B | 0.820 |
| 4 | 20100144.Her2HRpos | — | D | 0.816 |
| 5 | SRR5088886 | — | — | 0.815 |
| 6 | SRR8392888 | — | cohortMD1 | 0.810 |
| 7 | SRR5088885 | — | — | 0.808 |
| 8 | C3N-02435 | — | cohortSQ1 | 0.807 |
| 9 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.804 |
| 10 | TCGA-51-4081-01A-01R-1100-07 | — | cohortSQ2 | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| HYPOXIA | 0.030 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |